Patents Examined by Jennifer S Spence
  • Patent number: 12268714
    Abstract: Provided herein are a method for isolation and transplantation of intact mitochondria to a lymphoid organ (a primary lymphoid tissue or a secondary lymphoid tissue), a composition of cells prepared by using a method described herein, and a method for manufacturing cells described herein. In particular, provided herein are methods of isolating intact mitochondria from a donor cell. Also provided herein are methods of transplanting mitochondria into a recipient cell. In some aspects, the methods can be performed in vivo. Further provided are a composition of cells that include the cells prepared using the methods of the present invention.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: April 8, 2025
    Assignee: LUCA Science Inc.
    Inventors: Masashi Suganuma, Hideyoshi Harashima, Yuma Yamada, Daisuke Sasaki, Takafumi Yokota
  • Patent number: 12264337
    Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
    Type: Grant
    Filed: September 4, 2024
    Date of Patent: April 1, 2025
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: George Harb, Chunhi Xie
  • Patent number: 12234485
    Abstract: Provided is a resin film having excellent cell extensibility in cell culture. The resin film formed of a scaffold material for cell culture containing a synthetic resin, the resin film having a compressive modulus of 5.5 GPa or more at a frequency of 1 Hz as measured using a nanoindenter device in ion-exchanged water in accordance with ISO14577-1 after being immersed in the ion-exchanged water at 37° C. for 24 hours.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: February 25, 2025
    Assignee: SEKISUI CHEMICAL CO., LTD.
    Inventors: Yuuhei Arai, Ryoma Ishii, Hiroki Iguchi, Satoshi Haneda
  • Patent number: 12227765
    Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
    Type: Grant
    Filed: September 4, 2024
    Date of Patent: February 18, 2025
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: George Harb, Chunhi Xie
  • Patent number: 12173324
    Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: December 24, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: George Harb, Chunhui Xie
  • Patent number: 12161674
    Abstract: Provided herein, in some embodiments, are methods and compositions for treatment of subjects with ?-thalassemia and subjects with severe sickle cell disease using autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: December 10, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ewelina Morawa, Tirtha Chakraborty, Ante Sven Lundberg, Tony Ho, Laura Sandler, Brenda Eustace, Jerome Rossert, Robert Kauffman
  • Patent number: 12163156
    Abstract: The present invention relates to a cell induction method, in particular to a method for inducing differentiation of fibroblasts into adipocytes, comprising the following steps: Cultivating the fibroblasts in a culture medium, adding a Myosin inhibitor and BMP4 to the culture medium, and continuously cultivating same until adipocytes are obtained. The present invention further relates to a method for inducing the conversion of fibroblasts into immortalized cells and use thereof. The method comprises the following steps: cultivating the fibroblasts in a culture medium, adding Myosin inhibitor to the culture medium, and continuously cultivating same until immortalized cells are obtained. The present invention further relates to a method for inducing in vitro amplification of hepatocytes.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: December 10, 2024
    Assignee: INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES
    Inventors: Qi Zhou, Wei Li, Zhengquan He, Liu Wang
  • Patent number: 12146166
    Abstract: The present Application is related to methods and compositions for reprogramming adult somatic cells into induced pluripotent stem cells by targeting and remodeling endogenous gene loci without relying on ectopic expression of transcription factors.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: November 19, 2024
    Assignee: THE J. DAVID GLADSTONE INSTITUTES
    Inventors: Peng Liu, Sheng Ding
  • Patent number: 12134767
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: November 5, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Matthew Hebden Porteus
  • Patent number: 12129483
    Abstract: The three main peripheral sensory neuron (SN) subtypes, nociceptors, mechanoreceptors, and proprioceptors localize to dorsal root ganglia (DRG) and convey sensations such as pain, temperature, pressure and limb movement/position. Disclosed herein is a chemically defined differentiation protocol that generates all three SN subtypes from the same starting population, as well as methods to enrich for each individual subtypes. The protocol yields high efficiency and purity cultures that are electrically active and respond to specific stimuli. Their molecular character and maturity stage are described and evidence for their use as an axotomy model is exemplified. Cell populations and compositions formed from the resulting cells, as well as methods of their use for disease treatment, drug screening, and modeling of human disorders affecting SNs are also provided.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: October 29, 2024
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Nadja Zeltner, Vicente Kenyi Saito-Diaz
  • Patent number: 12121563
    Abstract: Selectively providing voltage-gated sodium channel function sufficient to rescue impaired Nav1.1 function to inhibitory neurons is described. Provided voltage-gated sodium channel function sufficient to rescue impaired Nav1.1 function in inhibitory neurons can be used to treat disorders such as epilepsy, and more particularly, Dravet Syndrome.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: October 22, 2024
    Assignees: Allen Institute, Seattle Children's Hospital
    Inventors: John K. Mich, Edward Sebastian Lein, Jonathan Ting, Boaz P. Levi, Erik Hess, Franck Kalume
  • Patent number: 12110503
    Abstract: Provided herein are methods of producing a photoreceptor precursor (PRP) cell population derived from stem cells. Further provided herein are methods of using the PRP cell populations, such as for therapeutics.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: October 8, 2024
    Assignee: FUJIFILM Cellular Dynamics, Inc.
    Inventors: Lucas Chase, Kyle Wallace, Benjamin Meline, Andrew Dias, Brandon Shelley, Marisa Fenn, Debjani Phillips, Matthew Sternfeld, Nathan Meyer
  • Patent number: 12097222
    Abstract: The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: September 24, 2024
    Assignee: Spiritus Therapeutics, Inc.
    Inventors: Jodi Gurney, Robin Smith
  • Patent number: 12098365
    Abstract: The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: September 24, 2024
    Assignee: GENENTECH, INC.
    Inventors: Michael Wilson Laird, Shahram Misaghi, Amy Shen, Anthony Tomlinson, Inn Huam Yuk
  • Patent number: 12077780
    Abstract: The production and use of extracellular matrix or conditioned medium compositions and more specifically to compositions obtained by culturing cells under hypoxic conditions on a surface in a suitable growth medium.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: September 3, 2024
    Assignee: ALLERGAN SALES, LLC
    Inventor: Patrick Nido
  • Patent number: 12060573
    Abstract: Stabilized amorphous calcium carbonate (ACC) as a supplement of cell culture media and the cell culture medium supplements comprising stabilized ACC are provided. In particular the stabilized ACC is useful for enhancing the growth of cell and tissue cultures, gametes and embryos in vitro.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: August 13, 2024
    Assignee: AMORPHICAL LTD.
    Inventors: Yosef Ben, Abraham Shahar, Amir Arav
  • Patent number: 12060576
    Abstract: Methods for producing megakaryocytic progenitors (preMKs) and megakaryocytes (MKs) from stem cells are provided. The present disclosure further provides compositions comprising preMKs and MKs and their lysates, and also methods of use of preMKs, MKs, their lysates and compositions thereof.
    Type: Grant
    Filed: January 5, 2019
    Date of Patent: August 13, 2024
    Assignee: Stellular Bio, Inc.
    Inventors: Jonathan Thon, Brad Dykstra
  • Patent number: 12049645
    Abstract: Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic ? cell, ? cell, ? cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: July 30, 2024
    Inventors: George Harb, Chunhui Xie
  • Patent number: 12036241
    Abstract: Compounds that either produce a higher proportion or greater absolute number of phenotypically identified naive, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies, such as those providing improvements in one or more therapeutic outcomes, are provided.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: July 16, 2024
    Assignees: FATE THERAPEUTICS, INC., JUNO THERAPEUTICS, INC.
    Inventors: Jonathan Rosen, Eigen Peralta, Ian Hardy, Betsy D. Rezner, Christian Maine, Daniel Shoemaker, David Robbins, Lucas Thompson
  • Patent number: 12031892
    Abstract: A method is provided for using hollow fibers having a porosity above 20 nm, in particular polyethersulfone hollow fibers, to impoverish blood and blood-derivatives from blood-derived extracellular vesicles, in particular exosomes and exomers. Methods for obtaining and analyzing the impoverished samples are also provided.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: July 9, 2024
    Assignee: Medica S.P.A.
    Inventors: Antonio Chiesi, Natasa Zarovni, Davide Zocco